AI with intent: How Inizio is redefining pharma through precision and partnership
October 29, 2025 | Intelligent Commercialization
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the future of Intelligent Commercialization™.
Empowering human insight at Fierce Pharma Week
This year’s Fierce Pharma Week brought together the leading voices shaping the future of pharmaceutical communications, strategy, and innovation. At Inizio, we had a front-row seat through the contributions of experts, who showcased how we’re combining human expertise with AI to deliver precision, credibility, and measurable impact.
Across every discussion our experts took part in, one theme stood out: AI delivers its greatest value when guided by intent. From elevating scientific storytelling to advancing field medical enablement and enabling data-driven decision-making, our teams demonstrated how purposeful integration of AI is transforming how pharma connects, learns, and leads.
Here’s how our experts brought that vision to life at Fierce Pharma Week through connected insight, practical innovation, and partnership that drives real-world change.
Engineering credibility in an AI-powered world
In the session “From earned to engineered,” Inizio Evoke’s Will Reese, Theresa Dolge, and Kelly Cusumano urged pharma communicators to rethink visibility in an AI-shaped world.
They discussed the rise of “thin” versus “thick” content, concise, discoverable insights that feed AI models versus deeply sourced narratives that build authority. The strongest brands balance both, ensuring that what AI learns is accurate, credible, and humanly resonant.
As Will noted, “AI rewards content that’s structured, traceable, and solution-oriented.” The key is designing material that both humans and machines can trust, because what’s visible shapes what’s believed.
Explore the full talk delivered by Inizio Evoke here.
Building real capability with real impact
AI delivers the most value when guided by experts who use it with purpose.
Inizio Medical’s Kelly Malloy, SVP of Customer Engagement for AI and Augmented Intelligence, brought this to life during her talk, “The business case for next-gen field medical enablement,” alongside a panel of industry leaders:
- Tiffanie Stewart, PhD, Senior Director, MSLs, Inizio Engage
- Donnie Wooten, Jr., PharmD, Senior Director, Global Medical Capabilities – Oncology, AstraZeneca
- Michael Kahn, formerly Senior Director, Medical Affairs Operations Leader, Spark Therapeutics
Using tools like MSL Interact, teams can rehearse realistic HCP conversations in a safe, simulated environment. It’s a powerful example of using AI to enhance human skills like empathy, curiosity, and dialogue, rather than aiming to replace them. The panel highlighted the value of adaptive, continuous learning along with a “Four Ps” model: prepare, practice, perform, pivot.
“Generative AI is an accelerant, not a shortcut,” Kelly reminded the audience. “When used deliberately, it bridges science and storytelling- helping field teams communicate more clearly and confidently in the moments that matter most.”
Watch the full talk delivered by Inizio Medical here.
Transforming medical affairs with data and AI
Inizio Advisory’s session, “Precision Medical Affairs in action,” led by Lori Klein, Partner, Medical Affairs Practice Lead, brought together expert insights from:
- Nikheel Kolatkar, VP, US Medical, Genentech
- Loucif Ouyahia, Global Head of Digital Healthcare, Jazz Pharmaceuticals
They described how precision Medical Affairs moves from reactive to predictive by using AI-driven analytics to uncover care gaps, localize insights, and personalize scientific engagement, connecting data across functions to create continuous feedback loops, and equip teams to partner confidently with AI.
As Lori summarized, “When you integrate human and machine intelligence, you don’t just find new insights – you create new impact.”
Watch Inizio Advisory’s Fierce Pharma Week session here.
Precision launch: aligning data, strategy, and purpose
In their second session, “Precision launch: Integrating data and AI to power commercial and medical strategy,” Inizio Advisory’s Jo-Ann Saitta, Partner, Global Data Strategy, and Lori Klein, spotlighted the value of data unity and strategic alignment.
Through centralized, compliant products like ClarityNav, part of the Navigator AI™ pharma teams can align next-best actions, understand the voice of the customer, and orchestrate personalized engagements. When medical and commercial teams operate from a single, trusted source of truth, every insight becomes actionable, and every action measurable.
This is what modern launch excellence looks like: predictive, connected, and powered by purpose.
Watch Inizio Advisory’s second Fierce Pharma Week session here.
Innovation rooted in the human equation
Every session echoed one essential truth: AI is only as valuable as the people guiding it. Whether in content, training, or analytics, Inizio’s approach to innovation is grounded in the belief that technology should elevate human creativity rather than eclipse it.
We’re building systems that help decision-makers within healthcare and pharma:
- See more clearly
- Decide more precisely
- Act with greater purpose
Because empathy, curiosity, and expertise, not algorithms, sustain trust in healthcare.
From insight to impact with Intelligent Commercialization™
Fierce Pharma Week reinforced our mission: to lead the future of Intelligent Commercialization™ – where human insight, data, and AI converge to deliver clarity, speed and measurable impact.
- Through strategic intelligence, Navigator AI™ enables faster, smarter portfolio and investment decisions, sharpens strategy, strengthens field execution, and accelerates launches.
- Through medical intelligence, iON.AI™ converts scientific evidence into actionable insights that enhance the influence and effectiveness of Medical Affairs execution.
- Through commercial intelligence, Cognitev™ translates primary generated behavioral data into activation – fueling omnichannel engagement, optimizing field force strategy, and aligning tactics across the lifecycle.
Together, we help the industry move beyond insight to action through accelerating launches, sharpening strategies, and driving real-world impact across the full lifecycle of commercialization.
Ready to unlock the power of Intelligent Commercialization™ across your organization?
Let’s talk about how using AI with intent can elevate your strategy, accelerate impact, and drive smarter engagement across the product lifecycle. Connect with our experts here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Research Partnership and Janssen are 2017-18 BOBI Awards finalists
We are delighted to announce that an entry submitted by Research Partnership with Janssen has been selected as a finalist in the Best Business Impact category at this year’s BOBI...
Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio
Tuesday 20th March 2018 11:00 EST / 16:00 GMT / 17:00 CEST
PMRC New Jersey round up 2018
Earlier this month, Directors Tom Nolte and Melinda Shorr attended the Pharmaceutical Market Research Conference in Newark, New Jersey
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of...
Good intentions, bad habits: Reforming mental healthcare in Latin America and the Caribbean
In the second of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Latin America and the Caribbean
How we applied user-led design thinking in the ER setting to improve patient care
The challengeOur client needed to identify the key delivery-device attributes for an antibiotic topical treatment used to combat a group of infections typically affecting young children. Current treatment is a...
Research conducted by Research Partnership published in leading medical journal
Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal
Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma...
Webcast: Rich in potential – Exploring the opportunity for nutritionals in emerging markets
Watch the webcast: http://bit.ly/2oTpzFjA shift to preventative health has seen nutritionals emerge as a rapidly developing area in recent years. But while growth begins to level off in more established territories,...
A researcher’s guide to Key Driver Analysis
Research Manager Kayleigh Simpson explores how Key Driver Analysis can be used to answer key business